FDA official announcements and approvals

DEA Increases Vyvanse Production Limit by 24% to Address ADHD Drug Shortage

Sep 4, 2024, 11:15 AM

The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the medication in the United States. This decision aims to mitigate the impact of the current drug shortage affecting ADHD treatment. The US is allowing 24% more production of Vyvanse and its generic rivals to address treatment shortages.